<DOC>
	<DOCNO>NCT02589158</DOCNO>
	<brief_summary>The purpose study look level three HIV medication : atazanavir , darunavir cobicistat blood drug intake stop , order understand long drug persist blood . The study specifically look blood level three drug take every day 10 day . Participants take Evotaz ( atazanavir cobicistat ) first stage Rezolsta ( darunavir cobicistat ) second stage . If participant decide take part , duration study 33 day plus screening visit take place 28 day prior start study , follow visit , take place 7 14 day last dose study medication . This study randomise mean participant receive study medication order . The participant study doctor know study medication participant take time study .</brief_summary>
	<brief_title>SSAT067 PK Atazanavir/Cobicistat Darunavir/Cobicistat</brief_title>
	<detailed_description>Protocol Number : SSAT067 EudraCT Number : 2015-002956-28 Name Investigational Product : Evotaz® , Rezolsta® Name active ingredient : Atazanavir , darunavir cobicistat Study title : Steady-state Pharmacokinetics Atazanavir/Cobicistat Darunavir/Cobicistat Once Daily Over 72 Hours Healthy Volunteers Phase study : Phase I Objectives : Primary : -To ass steady-state pharmacokinetics atazanavir/cobicistat darunavir/cobicistat 72 hour , HIV negative healthy volunteer . Secondary : - To assess inter subject variability atazanavir , darunavir cobicistat plasma concentration 72 hour - To assess safety tolerability atazanavir/cobicistat darunavir/cobicistat 10 day administration healthy volunteer - To investigate association genetic polymorphism drug disposition gene drug exposure Study design : 33 day ( exclude screen follow ) , open label , pharmacokinetic study . Indication : Not applicable Methodology : Measurements steady state pharmacokinetic profile plasma atazanavir/cobicistat darunavir/cobicistat male female healthy volunteer . Planned sample size : Up 30 male female healthy volunteer enrol baseline order achieve 16 complete study Summary eligibility criterion : Healthy participant determine medical history , physical examination , 12-lead electrocardiogram , clinical laboratory evaluation eligible participate study . Women childbearing potential must nurse pregnant . Women childbearing potential must negative pregnancy test screening . Number study centre : One Duration treatment : 33 day ( exclude screen follow visit ) Dose route administration : All participant administer Evotaz® ) ( atazanavir 300mg + cobicistat 150mg ) daily 10 day , undergo ten-day wash period take Rezolsta® ( darunavir 800mg + cobicistat 150mg ) daily 10 day . Criteria evaluation : - Pharmacokinetic parameter atazanavir/cobicistat evaluate blood drawn day 10 0 ( pre-dose ) , 1 , 2 , 3 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 hour post dose day 11 13 ( 72 hour post dose ) . - Pharmacokinetic parameter darunavir/cobicistat evaluate blood drawn day 30 0 ( pre-dose ) , 1 , 2 , 3 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 hour post dose day 31 33 ( 72 hour post dose ) . - Safety tolerability medication also assess question , physical examination laboratory parameter . These perform regular interval drug study . Primary Endpoint : -Steady state plasma concentration atazanavir/cobicistat darunavir/cobicistat 72 hour post-dose . Secondary End point : - Safety tolerability study drug 10 day administration . - Relationship genetic polymorphism exposure study drug .</detailed_description>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>1 . The ability understand sign write informed consent form , prior participation screening procedure must willing comply study requirement 2 . Male nonpregnant , nonlactating female 3 . Between 18 65 year , inclusive 4 . Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive 5 . ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A single repeat allow eligibility determination . 6 . Women childbearing potential ( WOCBP definition Appendix 5 ) must use adequate method contraception avoid pregnancy throughout study period least 4 week study A female may eligible enter participate study : 1. nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhea ≥ 45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy , 2. childbearing potential negative pregnancy test Screening Day 1 agrees use one follow method contraception avoid pregnancy : Complete abstinence penilevaginal intercourse 2 week prior administration IP , throughout study , least 4 week discontinuation study medication ; Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) ; Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ( IUDs meet criterion , see protocol appendix 5 example listing approve IUDs ) ; Male partner sterilization confirm prior female subject 's entry study , male sole partner subject ; Approved hormonal contraception ( see protocol appendix 5 listing example approve hormonal contraception ) plus male condom ; Any method publish data show expected failure rate &lt; 1 % per year . Any contraception method must use consistently , accordance approve product label least 4 week discontinuation IP . 7 . Men partner woman childbearing potential ( WOCBP definition Appendix 5 ) must use adequate method contraception avoid pregnancy partner throughout study period least 4 week study ( see inclusion criterion 6 ) 8 . Willing consent personal detail enter onto TOPS database 9 . Willing provide proof identity photographic ID screen subsequent visit 10 . Registered GP UK 1 . Any clinically significant acute chronic medical illness 2 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination 3 . Positive blood screen hepatitis B surface antigen C antibody 4 . Positive blood screen HIV1 2 antibody/antigen assay 5 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) 6 . History presence allergy darunavir , atazanavir cobicistat excipients ( sodium methyl parahydroxybenzoate , lactulose , Hypromellose Colloidal silicon dioxide , Silicified microcrystalline cellulose Crospovidone , Magnesium stearate , Polyvinyl alcohol partially hydrolyse , Macrogol 3350 , Titanium dioxide , Talc , Iron oxide red , Iron oxide black , Lactose monohydrate , Magnesium stearate , Gelatine Yellow iron oxide , Indigocarmin ( E132 ) , White ink , Shellac , Titanium dioxide ( E171 ) , Ammonium hydroxide , Propylene glycol , Simethicone , Hypromellose , Polyvinyl alcohol partially hydrolyse , Macrogol 3350 ) 7 . Current recent ( within 3 month ) gastrointestinal disease 8 . Known intolerance lactose monohydrate , sunset yellow aluminium lake ( E110 ) , patient galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption 9 . Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . Smoking permit , tobacco intake remain consistent throughout study 10 . Exposure investigational drug ( placebo ) participation clinical study involve donation blood sample within 3 month first dose study drug 11 . Use drug ( unless approve Investigator ) , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug . 12 . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 4 week end treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>